Reduction in Length of Hospital Stays for Allogeneic Hematopoietic Stem‐Cell Transplantation in the Letermovir Era
Transplant Infectious Disease · 2025
DOI: 10.1111/tid.70008 ↗Kurz gefasst
Fachartikel in der Zeitschrift Transplant Infectious Disease, 2025. Verfasst von Hiroki Hosoi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology/Oncology, Wakayama Medical University, Wakayama, Japan. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Cytomegalovirus Infections, Length of Stay, Antiviral Agents. Die Arbeit nennt 19 Literaturangaben. Gefördert von: JSPS KAKENHI, Takeda Science Foundation, Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Background
In recent years, letermovir has been routinely used for cytomegalovirus (CMV) infection prophylaxis in patients receiving allogeneic hematopoietic stem‐cell transplantation (HSCT). The reduction effect of letermovir on CMV infection rates and the impact on survival have been studied, but other potential benefits of letermovir remain underexplored.
Methods
This retrospective study included patients who underwent first‐time allogeneic HSCT between October 2013 and August 2023. We compared the length of hospital stay between eras before and after the introduction of letermovir (“nonletermovir group” and “letermovir group,” respectively). Secondary outcomes included clinically significant CMV infection rates and hospitalization costs.
Results
A total of 59 patients were analyzed in the nonletermovir group and 65 patients in the letermovir group. The median length of hospital stay was 51 days in the nonletermovir group and 42 days in the letermovir group ( p < 0.001). Among standard‐risk disease patients, the letermovir group also had significantly shorter hospital stays ( p = 0.0048). Additionally, the cumulative incidence of clinically significant CMV infection and grade II–IV acute graft‐versus‐host disease were both lower in the letermovir group. Hospitalization costs were not significantly different between the two groups.
Conclusion
The length of hospital stays after HSCT was observed to be shorter following the introduction of letermovir in this study. This reduction in hospital stays did not decrease hospitalization costs in relation to allogeneic HSCT, but it may alleviate the burden on both patients and healthcare providers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology/Oncology, Wakayama Medical University, Wakayama, Japan.
- Department of Transfusion Medicine, Wakayama Medical University Hospital, Wakayama, Japan.
- Clinical Study Support Center, Wakayama Medical University, Wakayama, Japan.
- Division of Medical Information, Wakayama Medical University Hospital, Wakayama, Japan.
ORCID-Profile: Hiroki Hosoi
Förderung
- JSPS KAKENHI
- Takeda Science Foundation
- Japan Society for the Promotion of Science
Zitieren
APA
Hosoi, H., Tane, M., Okamura, T., Tabata, S., Wan, K., Murata, S., Mushino, T., Nishikawa, A., & Sonoki, T. (2025). Reduction in Length of Hospital Stays for Allogeneic Hematopoietic Stem‐Cell Transplantation in the Letermovir Era. Transplant Infectious Disease. https://doi.org/10.1111/tid.70008
Vancouver
Hosoi H, Tane M, Okamura T, Tabata S, Wan K, Murata S, et al. Reduction in Length of Hospital Stays for Allogeneic Hematopoietic Stem‐Cell Transplantation in the Letermovir Era. Transplant Infectious Disease. 2025. doi:10.1111/tid.70008
BibTeX
@article{Hosoi2025,
author = {Hosoi, Hiroki and Tane, Misato and Okamura, Tadashi and Tabata, Shotaro and Wan, Ke and Murata, Shogo and Mushino, Toshiki and Nishikawa, Akinori and Sonoki, Takashi},
title = {Reduction in Length of Hospital Stays for Allogeneic Hematopoietic Stem‐Cell Transplantation in the Letermovir Era},
journal = {Transplant Infectious Disease},
year = {2025},
doi = {10.1111/tid.70008}
}
EUVIMED